Eteplirsen: A Breakthrough Treatment for Duchenne Muscular Dystrophy - Where is it Approved?
Duchenne muscular dystrophy (DMD) is a devastating genetic disorder that affects approximately 1 in 3,500 boys worldwide. It is characterized by progressive muscle weakness and degeneration, leading to loss of mobility, respiratory failure, and premature death. Despite the lack of a cure, researchers have made significant progress in developing treatments that can slow down the progression of the disease. One such treatment is eteplirsen, a exon-skipping antisense oligonucleotide that has shown promising results in clinical trials.
What is Eteplirsen?
Eteplirsen is a medication developed by Sarepta Therapeutics that works by skipping over a section of genetic code in the dystrophin gene, allowing for the production of a shorter but functional dystrophin protein. This approach has been shown to improve muscle function and reduce muscle degeneration in patients with DMD.
Where is Eteplirsen Approved?
Eteplirsen has been approved for distribution in several countries around the world. As of 2022, the countries where eteplirsen is approved for distribution are:
United States
Eteplirsen was approved by the US Food and Drug Administration (FDA) in September 2016 under the accelerated approval pathway. The approval was based on the results of a phase II clinical trial that showed significant improvements in muscle function and reduced muscle degeneration in patients treated with eteplirsen.
Canada
Eteplirsen was approved by Health Canada in November 2016 for the treatment of DMD in patients with a confirmed mutation in the dystrophin gene.
European Union
Eteplirsen was approved by the European Medicines Agency (EMA) in July 2019 for the treatment of DMD in patients with a confirmed mutation in the dystrophin gene.
Australia
Eteplirsen was approved by the Therapeutic Goods Administration (TGA) in Australia in August 2020 for the treatment of DMD in patients with a confirmed mutation in the dystrophin gene.
Other Countries
While eteplirsen is not yet approved in many countries, several countries are currently reviewing its application. According to DrugPatentWatch.com, eteplirsen has been filed for approval in several countries, including Japan, Switzerland, and the United Kingdom.
What's Next?
While the approval of eteplirsen is a significant step forward in the treatment of DMD, there is still much work to be done. Researchers are continuing to study eteplirsen and other potential treatments for DMD, and several new therapies are currently in development.
Key Takeaways
* Eteplirsen is a breakthrough treatment for Duchenne muscular dystrophy that has been approved for distribution in several countries.
* The medication works by skipping over a section of genetic code in the dystrophin gene, allowing for the production of a shorter but functional dystrophin protein.
* Eteplirsen has been shown to improve muscle function and reduce muscle degeneration in patients with DMD.
Frequently Asked Questions
1. What is eteplirsen used to treat?
Eteplirsen is used to treat Duchenne muscular dystrophy, a genetic disorder that affects muscle function and leads to progressive muscle weakness and degeneration.
2. How does eteplirsen work?
Eteplirsen works by skipping over a section of genetic code in the dystrophin gene, allowing for the production of a shorter but functional dystrophin protein.
3. Is eteplirsen approved in my country?
Eteplirsen is approved for distribution in several countries, including the United States, Canada, the European Union, and Australia. However, it is not yet approved in many countries. You can check with your local health authorities to see if eteplirsen is approved in your country.
4. What are the side effects of eteplirsen?
The most common side effects of eteplirsen include injection site reactions, fever, and headache.
5. How do I get access to eteplirsen?
Eteplirsen is typically prescribed by a doctor and administered through a series of injections. You can talk to your doctor about whether eteplirsen is right for you and how to access it.
Sources
1. Sarepta Therapeutics. (2022). Eteplirsen: Product Information.
2. FDA. (2016). FDA Approves Exondys 51 to Treat Duchenne Muscular Dystrophy.
3. Health Canada. (2016). Notice of Compliance: Exondys 51.
4. EMA. (2019). Eteplirsen: Summary of Product Characteristics.
5. TGA. (2020). Eteplirsen: Product Information.
6. DrugPatentWatch.com. (2022). Eteplirsen: Patent and Approval Status.